AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s
Executive Summary
Data showing superiority on endoscopic remission and non-inferiority on clinical remission could position AbbVie’s IL-23 inhibitor to move ahead of Stelara in treatment paradigm.